Back to Search Start Over

Novel surrogate virus neutralization test reveals low serum neutralizing anti-SARS-CoV-2-S antibodies levels in mildly affected COVID-19 convalescents

Authors :
Mustafa Yilmaz
Isabelle Pink
Christiane Ritter
Christian Schultze-Florey
Saskia C. Stein
Georg M. N. Behrens
Anne Cossmann
Nina Gödecke
Marius M. Hoeper
Jörg Martens
Hannah Kleine-Weber
Reinhold Förster
Stefanie Willenzon
Berislav Bošnjak
Anne Katrin Cordes
Rainer Blasczyk
Stefan Pöhlmann
Markus Hoffmann
Inga Ravens
Günter Bernhardt
Wolfram Puppe
Thomas F. Schulz
Publication Year :
2020
Publisher :
Cold Spring Harbor Laboratory, 2020.

Abstract

Neutralizing antibodies targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry into cells using surface-expressed angiotensin-converting enzyme 2 (ACE2). We developed a surrogate neutralization test (sVNT) to assess at what degree serum antibodies interfere with the binding of SARS-CoV-2-S-RBD to ACE2. The sVNT revealed neutralizing anti-SARS-CoV-2-S antibodies in the sera of 90% of mildly and 100% of severely affected coronavirus-disease-2019 (COVID-19) convalescent patients. Importantly, sVNT results correlated strongly to the results from pseudotyped-vesicular stomatitis virus-vector-based neutralization assay and to levels of anti-SARS-CoV-2-S1 IgG and IgA antibodies. Moreover, levels of neutralizing antibodies also correlated to duration and severity of clinical symptoms, but not patient age or gender. These findings together with the sVNT will not only be important for evaluating the prevalence of neutralizing antibodies in a population but also for identifying promising plasma donors for successful passive antibody therapy.

Details

Language :
English
Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....9acd882f53e087de540b080e29abe51c
Full Text :
https://doi.org/10.1101/2020.07.12.20151407